A study on efficacy and safety of insulin degludec/insulin aspart in patients with type 2 diabetes

A prospective study on efficacy and safety of insulin degludec/insulin aspart compared to insulin glargine and the relation with glycemic variability in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0004597

Enrollment

Registered

2020-01-03

Start date

2020-10-07

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Insulin degludec/Insulin aspart (Ryzodeg®) and Insulin glargine (Lantus®), 100U/mL for subcutaneous injection, Injection before the main meal in a day Switching on a 1:1 unit basis from their

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inclusion: 1. patients in the outpatient clinic of SNUH, with type 2 diabetes 2. age > 19 years 3. under treatment with once-daily basal insulin (= 7% and <=10% 5. marked postprandial hyperglycemia estimated by FPG and HbA1c 6. No change in blood sugar lowering medication taken during the study period

Exclusion criteria

Exclusion criteria: exclusion: 1. Type 1 diabetes 2. When using insulin other than Insulin glargine U100, Insulin glargine U300, and insulin degludec 3. pregnancy, breast feeding 4. major CVD events or malignancy with the past 6 months 5. uncontrolled hypertension 6. any medications or serious diseases known to significantly affect weight or glucose metabolism 7. irregular diet

Design outcomes

Primary

Measure	Time frame
HbA1c difference between the 2 insulins	—

Secondary

Measure	Time frame
hypoglycemic events	—

Countries

Korea, Republic of

Contacts

Public ContactHye Seung Jung

Seoul National University Hospital

jungjhs@gmail.com+82-2-2072-0240

Outcome results